In the clinical perspective, BRAF oncogenic activation confers a worse prognosis to human colorectal [26–29] and thyroid [30] carcinomas and melanomas [31, 32] and is linked to unresponsiveness to traditional and molecular targeted anticancer agents [9–11] and radioiodine [33]. This evidence concerns the gene BRAF and melanoma.